国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2010年
11期
661-664
,共4页
黄芸%欧阳海峰%吴朔%王文雅%吴昌归
黃蕓%歐暘海峰%吳朔%王文雅%吳昌歸
황예%구양해봉%오삭%왕문아%오창귀
哮喘%气道炎症%间充质干细胞%小鼠
哮喘%氣道炎癥%間充質榦細胞%小鼠
효천%기도염증%간충질간세포%소서
Ashma%Airway inflammation%Mesenchymal stem cells%Mice
目的 观察鸡卵清蛋白诱导小鼠支气管哮喘(简称哮喘)模型中外源性间充质干细胞(mesenchymal stem cells,MSC)在哮喘小鼠肺组织气道炎症中的作用.方法 45只雌性SPF级C57BL/6小鼠,体质量18~22 g.随机分为对照组(P:P:P)、哮喘组(O:P:O)和MSC治疗组(O:M:O).哮喘组与MSC治疗组第1天和第8天致敏,第15天、第16天和第17天使用OVA气道内滴入激发哮喘.MSC治疗组于哮喘造模第14天移植外源性MSC.对照组小鼠予PBS处理.三组小鼠于末次激发结束后24 h(第18天)处死,取支气管肺泡灌洗液上清,ELISA检测IL-5、IL-9及β-氨基己糖苷酶;支气管肺泡灌洗液细胞计数总细胞数、嗜酸粒细胞数;取肺组织行病理切片苏木精-伊红染色观察肺部气道炎症情况.结果 ①MSC下调了哮喘小鼠气道局部炎症;②MSC减轻了哮喘小鼠肺组织中的炎细胞浸润;③MSC减轻了哮喘小鼠气道中的肥大细胞脱颗粒现象;④MSC抑制了哮喘小鼠过度的Th2变态反应.结论 外源性MSC通过抑制Th2变态反应,减轻哮喘肺组织的气道炎症.
目的 觀察鷄卵清蛋白誘導小鼠支氣管哮喘(簡稱哮喘)模型中外源性間充質榦細胞(mesenchymal stem cells,MSC)在哮喘小鼠肺組織氣道炎癥中的作用.方法 45隻雌性SPF級C57BL/6小鼠,體質量18~22 g.隨機分為對照組(P:P:P)、哮喘組(O:P:O)和MSC治療組(O:M:O).哮喘組與MSC治療組第1天和第8天緻敏,第15天、第16天和第17天使用OVA氣道內滴入激髮哮喘.MSC治療組于哮喘造模第14天移植外源性MSC.對照組小鼠予PBS處理.三組小鼠于末次激髮結束後24 h(第18天)處死,取支氣管肺泡灌洗液上清,ELISA檢測IL-5、IL-9及β-氨基己糖苷酶;支氣管肺泡灌洗液細胞計數總細胞數、嗜痠粒細胞數;取肺組織行病理切片囌木精-伊紅染色觀察肺部氣道炎癥情況.結果 ①MSC下調瞭哮喘小鼠氣道跼部炎癥;②MSC減輕瞭哮喘小鼠肺組織中的炎細胞浸潤;③MSC減輕瞭哮喘小鼠氣道中的肥大細胞脫顆粒現象;④MSC抑製瞭哮喘小鼠過度的Th2變態反應.結論 外源性MSC通過抑製Th2變態反應,減輕哮喘肺組織的氣道炎癥.
목적 관찰계란청단백유도소서지기관효천(간칭효천)모형중외원성간충질간세포(mesenchymal stem cells,MSC)재효천소서폐조직기도염증중적작용.방법 45지자성SPF급C57BL/6소서,체질량18~22 g.수궤분위대조조(P:P:P)、효천조(O:P:O)화MSC치료조(O:M:O).효천조여MSC치료조제1천화제8천치민,제15천、제16천화제17천사용OVA기도내적입격발효천.MSC치료조우효천조모제14천이식외원성MSC.대조조소서여PBS처리.삼조소서우말차격발결속후24 h(제18천)처사,취지기관폐포관세액상청,ELISA검측IL-5、IL-9급β-안기기당감매;지기관폐포관세액세포계수총세포수、기산립세포수;취폐조직행병리절편소목정-이홍염색관찰폐부기도염증정황.결과 ①MSC하조료효천소서기도국부염증;②MSC감경료효천소서폐조직중적염세포침윤;③MSC감경료효천소서기도중적비대세포탈과립현상;④MSC억제료효천소서과도적Th2변태반응.결론 외원성MSC통과억제Th2변태반응,감경효천폐조직적기도염증.
Objective To study the suppression of allergic airway inflammation in a mouse model of asthma by exogenous mesenchymal stem cells (MSC). Methods Forty five C57BL/6 mice were randomly divided into three groups:control group (15) ,asthmatic group (15) and MSC treated group (15). Asthma and MSC treatment groups were sensitized i. p. with OVA on day 1 and 8. Then, mice were challenged with OVA by the intratracheal route on day 15,16 and 17. On day 14,exogenous MSC (1× l06 cells in 1ml PBS) were administered through the tail vein to mice 1 day before the first airway challenge in the MSC treated group. Control mice were treated with PBS. Mice were sacrificed on day 18. BALF were
obtained and centrifuged to pellets and supernatants. Pellets recovered for cellular analysis. Supernatants were stored at-80 for biochemical analyses. The total number of cells in BALF was counted and the eosinophils. Concentration of IL-5, IL-9 in BALF were determined. To detect β-hexosaminidase activity.The paraffin embedded sections of lung tissue were stained with HE and the lung pathological changes were observed. Results ①Airway inflammation were significantly reduced by exogenous MSC. ②Administration of exogenous MSC significantly reduced airway cellular infiltrates. ③Mast cell degranulation were significantly reduced by exogenous MSC. ④Administration of exogenous MSC reversed the Th2 Bias.Conclusions Exogenous MSC reduced airway inflammation of allergic asthmatic mice through the reversion of Th2 Bias.